Cboe Europe EUR

Guerbet (GBTP.XD)

Compare

19.77

-0.33

(-1.64%)

At close: April 11 at 5:29:25 PM GMT+2

GUERBET : 2024 full-year results.

2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER)1 and on a like-for-like basis2Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA excluding France (+8.8%) Solid increase in profitability Restated EBITDA margin3 of 14.9%, versus 13.1% a year earlierOperating income up 28.2% to €49.6 million 2025 targets Further growth in profitability: restated EBITDA margin expected above 15%, b

GlobeNewswire 16 days ago

GBT.PA
DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions on CT scan.

DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions onCT scan The first CE-marked IA for the detection of bones lesionsA world premier : an innovate solution expected of the entire medical professionEnhancement of DUOncoTM, IA range for integration into medical imaging systems Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-m

GlobeNewswire 24 days ago

GBT.PA
GUERBET : 2024 revenue.

2024 revenue Solid growth momentum for the second year in a row Full-year revenue: €841.1 million, with growth of 9.0% on a like-for-like basis and at CERThis performance was achieved thanks to strong momentum in the Americas (+20.5%) and Asia (+10.1%) and despite the contraction of activity in France Details on the 2024 financial statements Expected Restated EBITDA margin close to 14.9%Free cash flow expected to be slightly negativeSignificant improvement in financial leverage (net debt/EBITDA)

GlobeNewswire 2 months ago

GBT.PA
GUERBET : Implementation of a Liquidity Contract with NATIXIS ODDO BHF

Implementation of a Liquidity Contract with NATIXIS ODDO BHF Villepinte, 3 February 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, ends its liquidity contract ongoing since 9 March 2022 and announces having appointed NATIXIS and ODDO BHF to implement a liquidity contract, starting on 3 February 2025, for a period of one year tacitly renewable. This contract complies with the decision of the Autorité des marchés financiers (AMF) n°2021-

GlobeNewswire 2 months ago

GBT.PA
Correction: GUERBET : Financial agenda for 2025

CORRECTION - Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications calendar 2024 ANNUAL REVENUE February 06, 2025, after trading 2024 ANNUAL RESULTS March 26, 2025, after trading 2025 1st QUARTER REVENUE April 24, 2025, after trading ANNUAL SHAREHOLDERS’ MEETING May 23, 2025 2025 2nd QUARTER REVENUE July 24, 2025, after trading 2025 FIRS

GlobeNewswire 2 months ago

GBT.PA
GUERBET : Financial agenda for 2025

Financial agenda for 2025 Villepinte, 31 October 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications calendar 2024 ANNUAL REVENUE February 06, 2025, after trading 2024 ANNUAL RESULTS March 27, 2025, after trading 2025 1st QUARTER REVENUE April 24, 2025, after trading ANNUAL SHAREHOLDERS’ MEETING May 23, 2025 2025 2nd QUARTER REVENUE July 24, 2025, after trading 2025 FIRST HALF RESULT

GlobeNewswire 5 months ago

GBT.PA
GUERBET : Revenue at September 30, 2024.

Revenue at September 30, 2024 Continued growth momentum 9-month revenue: €620.5m, up 9.6% at CER1 In the third quarter, momentum remained strong (+5.4% at CER), driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was once again impacted by the continued implementation of the new supply chain in France 2024 annual targets confirmed Revenue: expected growth of over 9%on a like-for-like basis and at CERProfitability: re-stated EBITDA margin returnedto a higher level

GlobeNewswire 5 months ago

GBT.PA
GUERBET : H1 2024 results.

H1 2024 results Very dynamic business activity H1 revenue: €419.2m, up 11.8% at CER1 A trajectory driven by all activities and geographical areas Solid increase in profitability The restated EBITDA margin2 was 15.4%, compared to 12.7% a year earlierOperating income almost tripled to €30.3m Upward revision of annual guidance Revenue: expected growth of over 9% like-for-like and at CER (>8% previously)Profitability: restated EBITDA margin rate higher than in 2021 (14.4%) Villepinte, 25 September 2

GlobeNewswire 6 months ago

GBT.PA
GUERBET : H1 2024 revenue.

H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER1, including an acceleration in Q2 (+14.5%)This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in France and MRI sales Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 July 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and s

GlobeNewswire 8 months ago

GBT.PA
Exploring Undervalued Opportunities on Euronext Paris With Edenred and Two More Stocks

As European markets experience a modest uplift, with France's CAC 40 Index seeing a gain of 0.63%, investors are keenly watching for opportunities that might be lurking beneath the surface of broad market movements. In this context, identifying undervalued stocks becomes particularly compelling, offering potential for those looking to invest in assets that may not yet reflect their intrinsic value given the current economic environment.

Simply Wall St. 8 months ago

GBT.PA

VIVEF

VIVHY
Airbus And Two Additional Stocks Estimated To Be Undervalued On Euronext Paris

Amidst a turbulent week for European markets, where political uncertainty and economic indicators painted a mixed picture, investors are keenly observing potential opportunities. In this context, identifying undervalued stocks such as Airbus on the Euronext Paris could be particularly intriguing for those looking to capitalize on discrepancies between current market prices and intrinsic values.

Simply Wall St. 9 months ago

TKKHF

EADSF

EADSY
Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.

Hugues Lecat appointed Chairman of the Board of Directors of Guerbet Villepinte, 24 May 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is announcing the appointment of Hugues Lecat as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release of 20 March 2024). Following the approval of his appointment as director at the Annual General Meeting held today at the registered office, the Boar

GlobeNewswire 10 months ago

GBT.PA
Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.

NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics -- Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies, production, and commercialization with Nuclidium’s in depth know-how of the copper radioisotope production and theranostic development -- Basel, Switzerland and Villepinte, France, May 22, 2024 – NUCLIDIUM and Guerbet (GBT) today announced a strategic partnership to advance NUCLIDI

GlobeNewswire 10 months ago

GBT.PA
Guerbet : Q1 2024 revenue.

Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a g

GlobeNewswire 11 months ago

GBT.PA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Guerbet (GBTP.XD)

GUERBET : 2024 full-year results.

DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions on CT scan.

GUERBET : 2024 revenue.

GUERBET : Implementation of a Liquidity Contract with NATIXIS ODDO BHF

Correction: GUERBET : Financial agenda for 2025

GUERBET : Financial agenda for 2025

GUERBET : Revenue at September 30, 2024.

GUERBET : H1 2024 results.

GUERBET : H1 2024 revenue.

Exploring Undervalued Opportunities on Euronext Paris With Edenred and Two More Stocks

Airbus And Two Additional Stocks Estimated To Be Undervalued On Euronext Paris

Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.

Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.

Guerbet : Q1 2024 revenue.